文献速递白血病淋巴瘤

维奈克拉剂量递增快速激活慢性淋巴细胞白血病中的BAFF/BCL-2生存轴

Venetoclax dose escalation rapidly activates a BAFF/BCL-2 survival axis in chronic lymphocytic leukemia.
PubMed 文献 · Blood · 2024-01-01

研究对慢性淋巴细胞白血病(CLL)患者维奈克拉单药治疗前5周的外周血细胞进行纵向质谱流式分析,发现维奈克拉显著减少所有CLL亚群,但存活细胞中BCL-2、BCL-extra large和MCL-1等促生存蛋白快速上调且药物敏感性降低;小鼠模型重现该现象并显示广泛凋亡和BAFF可及性是关键;接受维奈克拉或奥妥珠单抗治疗的患者中BAFF显著升高、白血病细胞促生存蛋白增加,提示可联合靶向细胞因子信号以获更深更持久缓解。

要点

  • 维奈克拉治疗早期即显著减少所有CLL亚群,但存活细胞促生存蛋白BCL-2、BCL-extra large和MCL-1快速上调。
  • 小鼠模型证实维奈克拉诱导的B细胞和CLL样细胞生存蛋白持续升高,广泛凋亡和BAFF可及性为必要条件。
  • 维奈克拉或奥妥珠单抗治疗患者中BAFF显著升高、白血病细胞促生存蛋白增加,支持联合靶向细胞因子信号。

核心结论

  • CLL细胞通过稳态因子快速适应靶向治疗,支持联合靶向细胞因子信号以实现更深、更持久的长期缓解。

研究设计与样本

  • 对CLL患者维奈克拉单药治疗前5周的外周血细胞进行纵向质谱流式分析,并在小鼠模型中进行验证。

主要发现

  • 维奈克拉诱导所有CLL亚群显著减少,同时存活细胞中BCL-2、BCL-extra large和MCL-1蛋白快速上调,且对药物敏感性降低。
  • 小鼠模型中维奈克拉诱导的B细胞和CLL样细胞生存蛋白升高可重现,遗传模型显示广泛凋亡和BAFF可及性是必要条件。
  • 接受维奈克拉或奥妥珠单抗治疗的CLL患者中BAFF显著升高,白血病细胞促生存蛋白增加并持续存在。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Venetoclax, a first-in-class BH3 mimetic drug that targets B-cell lymphoma-2 (BCL-2), has improved the outcomes of patients with chronic lymphocytic leukemia (CLL). Early measurements of the depth of the venetoclax treatment response, assessed by minimal residual disease, are strong predictors of long-term clinical outcomes. However, there are limited data on the early changes induced by venetoclax treatment that might inform strategies to improve responses. To address this gap, we conducted longitudinal mass cytometric profiling of blood cells from patients with CLL during the first 5 weeks of venetoclax monotherapy. At baseline, we resolved CLL heterogeneity at the single-cell level to define multiple subpopulations in all patients based on proliferative, metabolic, and cell survival proteins. Venetoclax induced a significant reduction in all CLL subpopulations and caused rapid upregulation of the prosurvival BCL-2, BCL-extra large, and mantle cell lymphoma-1 proteins in surviving cells, which had reduced sensitivity to the drug. In mouse models, the venetoclax-induced elevation of survival proteins in B cells and CLL-like cells that persisted was recapitulated, and genetic models demonstrated that extensive apoptosis and access to the B-cell cytokine, B-cell activating factor (BAFF), were essential. Accordingly, in patients with CLL who were treated with venetoclax or the anti-CD20 antibody obinutuzumab there was marked elevation in BAFF and an increase in prosurvival proteins in leukemic cells that persisted. Overall, these data highlight the rapid adaptation of CLL cells to targeted therapies through homeostatic factors and support cotargeting of cytokine signals to achieve deeper and more durable long-term responses.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Luo MX, Tan T, Trussart M, et al. Venetoclax dose escalation rapidly activates a BAFF/BCL-2 survival axis in chronic lymphocytic leukemia. Blood. 2024. PMID: 39471335. doi:10.1182/blood.2024024341

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。